Hebei Medical University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1894-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.hebmu.edu.cn
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT03986385
- Locations
- 🇨🇳
QunZhao, Shijia Zhuang, Hebei, China
Repair of Thumb Defect by Using the Toe Nail Flap
Completed
- Conditions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 29
- Registration Number
- NCT03879941
A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 36
- Registration Number
- NCT03718624
A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 38
- Registration Number
- NCT03428425
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT03368131
- Locations
- 🇨🇳
Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT03349866
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, ShiJiaZhuang, Hebei, China
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT03219801
- Locations
- 🇨🇳
the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Gingiva Mesenchymal Stem Cells Treatment of Chronic Periodontitis
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT03137979
- Locations
- 🇨🇳
the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT03055078
- Locations
- 🇨🇳
the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT02510469
- Locations
- 🇨🇳
Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
© Copyright 2024. All Rights Reserved by MedPath